Special Issue "Influenza Viruses Epidemiology and Vaccination: State-of-the-Art Research in Europe"
Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 2842
Influenza is a serious threat to human health and a significant source of direct and indirect costs for the implementation of control measures and the management of cases and complications of the disease. It is responsible for an estimated 50 million disease episodes and 15,000 to 70,000 deaths in the European Union.
Before the current emergency of SARS-CoV-2 pandemic, the last pandemic event was recorded in 2009, and was cause by the global diffusion of a new influenza virus—A(H1N1)pdm09—which mainly affected young adults and caused over half a million deaths worldwide. The last influenza pandemic highlighted the need to implement more stringent monitoring of variants of potentially pandemic human and non-human influenza viruses. Laboratory surveillance is acknowledged to be an indispensable tool. Moreover, in recent years, it has enabled the development of new, more rapid, and better performing molecular tests that are able to gather information on the phylogenetic evolution of the viruses themselves.
Due to the frequent genetic and antigenic changes in influenza viruses, the seasonal vaccine is regularly reformulated (almost annually) to adapt to the characteristics of circulating viruses and annual vaccination is recommended. Vaccination is considered to be the most effective means of preventing the flu and its complications.
This Special Issue is focused on the design and implementation of suitable integrated systems of surveillance and of differential laboratory diagnosis that are, therefore, of crucial importance in the early identification of health emergencies, in order to enable the prompt containment of infections and coinfections in the population and facilitate the activation of adequate preventive strategies (including vaccination programs). Based on your extensive knowledge and experience, we invite you to contribute with original report, or review on influenza vaccines, other vaccines specifically designed for at-risk categories, on the prevention strategies of other future possible pandemics, and on epidemiological and virological influenza surveillance.
Dr. Ilaria Manini
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- influenza vaccine